Unraveling the Complex Web: Heart, Kidney, and Metabolism
The Silent Killer: Uncovering the Interconnectedness of Cardiovascular and Kidney Health
At the forefront of medical research, Boehringer Ingelheim is making waves with its dedicated focus on cardio-kidney-metabolic research. The company's presence at the American Heart Association Scientific Sessions 2025 in New Orleans showcased its long-standing commitment to pushing the boundaries of innovation in this critical area of healthcare.
Neerja Balachander, MBBS, PhD, a key figure at Boehringer Ingelheim, highlighted the company's unique approach. With over 140 years of experience in human and animal health, Boehringer Ingelheim's priority is clear: improving family and patient well-being, not just shareholder profits. This perspective has guided their pioneering work, from studying empagliflozin for cardiovascular risk reduction and chronic kidney disease to developing therapies for obesity and metabolic-associated steatohepatitis (MASH).
But here's where it gets controversial: the heart and kidney connection. Dr. Balachander explains that the kidney, with its intricate network of tiny filters, is a window into the health of our blood vessels. When these vessels are compromised, as in diabetes, the kidney becomes a tell-tale sign of endothelial dysfunction. And this is the part most people miss: kidney disease is not just a kidney issue; it's a systemic problem that can lead to heart attacks and heart-related complications, with research showing a six-fold increased risk.
The challenge? Nine out of ten patients with chronic kidney disease are unaware of their condition. The solution? A simple, inexpensive test to measure the albumin-to-creatinine ratio in urine. This test, Dr. Balachander argues, should be a routine part of healthcare, just like checking blood pressure or cholesterol levels.
Breaking Down Silos: A Call for Action
Pharmacy Times delved into this issue, asking how understanding this interconnectedness can improve early intervention and long-term risk reduction for cardiovascular events. Dr. Balachander's response was clear: education and implementation. In cardiology practice, not assessing diabetic status or blood pressure would be considered malpractice. Yet, urine testing, a vital tool for early detection, has been overlooked, a victim of medical silos.
However, there's hope. Organizations like the National Kidney Foundation (NKF), the American Diabetes Association (ADA), and the American Heart Association (AHA) are working to simplify the process. They're partnering with companies like Boehringer Ingelheim to develop concise, actionable lists of risk factors that clinicians can easily incorporate into their daily practice.
Boehringer Ingelheim's Vision: A Holistic Approach to Patient Care
Pharmacy Times further explored Boehringer Ingelheim's leadership in advancing therapies across the cardio-renal-metabolic spectrum. Dr. Balachander emphasized that, as a family-owned company, Boehringer Ingelheim's focus is on family health, not Wall Street. With a majority of the world's population suffering from cardio-kidney-metabolic conditions, addressing these interconnected issues is a natural extension of their work.
The company's journey with empagliflozin, originally developed for diabetes, exemplifies this holistic approach. Empagliflozin's success in reducing cardiovascular risk and its impact on kidney health has paved the way for further research into chronic kidney disease, strengthening the cardio-kidney connection. With ongoing investments in therapies like survodutide, vicasatostat, and empagliflozin, Boehringer Ingelheim is dedicated to improving patient outcomes across the cardio-kidney-metabolic spectrum.
As we navigate the complex web of heart, kidney, and metabolic health, Boehringer Ingelheim's commitment to integrated therapeutic development offers a beacon of hope. Their work reminds us of the importance of a holistic approach to healthcare, where understanding the interconnectedness of our bodies can lead to better, more effective treatments.
